Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Thymia has developed a proprietary AI-driven digital biomarker platform that combines voice, video, and behavioral data to objectively assess and monitor mental health. Their technology demonstrates up to ~84% accuracy in detecting depression and anxiety. The company’s "Helios" product addresses workplace wellness while the "Apollo" product targets clinical diagnosis of depression, anxiety, and ADHD. Apollo remains an investigational device as of mid–2025. The company has rapidly expanded globally with clients across five continents.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Thymia.